Alfonso Galderisi, MD, PhD
he/him/his
Assistant ProfessorCards
About
Research
Publications
2024
Correction: Quantifying beta cell function in the preclinical stages of type 1 diabetes
Galderisi A, Carr A, Martino M, Taylor P, Senior P, Dayan C. Correction: Quantifying beta cell function in the preclinical stages of type 1 diabetes. Diabetologia 2024, 1-2. PMID: 39592509, DOI: 10.1007/s00125-024-06335-w.Peer-Reviewed Original ResearchContinuous Glucose Monitoring among Infants Born Very Preterm: Evidence for Accuracy in Neonatal Intensive Care
Bonet J, Guiducci S, Res G, Brigadoi S, Sen S, Montaldo P, Priante E, Santoro N, Trevisanuto D, Baraldi E, Man C, Galderisi A. Continuous Glucose Monitoring among Infants Born Very Preterm: Evidence for Accuracy in Neonatal Intensive Care. The Journal Of Pediatrics 2024, 114416. PMID: 39579867, DOI: 10.1016/j.jpeds.2024.114416.Peer-Reviewed Original ResearchBlood glucoseContinuous glucose monitoringSensor glucoseNeonatal intensive care unitInfants born pretermWeeks of gestationNeonatal intensive careIntensive care unitVery pretermGlucose monitoringCare unitIntensive carePoint-of-care blood glucoseInfantsPretermNeonatesPaired measurementsCGM accuracyHoursBirthweightGestationGlucoseBirthWeeksTrajectory of beta cell function and insulin clearance in stage 2 type 1 diabetes: natural history and response to teplizumab
Galderisi A, Sims E, Evans-Molina C, Petrelli A, Cuthbertson D, Nathan B, Ismail H, Herold K, Moran A. Trajectory of beta cell function and insulin clearance in stage 2 type 1 diabetes: natural history and response to teplizumab. Diabetologia 2024, 1-16. PMID: 39560746, DOI: 10.1007/s00125-024-06323-0.Peer-Reviewed Original ResearchProgrammed death-1AUC C-peptideSlow progressorsRapid progressorsInsulin secretionInsulin clearanceC-peptideDisease-free survival ratesT effector memory cellsCD8+ T effector memory cellsNatural historyImpact of immunotherapyPlacebo-treated individualsT memory cellsBaseline insulin secretionBeta cell functionInterpreting clinical trialsLoss of insulin secretionDeath-1Elevated insulin secretionPlacebo-treatedTreatment armsTeplizumabClinical trialsDisposition indexAdipose Tissue Insulin Resistance in Children and Adolescents: Linking Glucose and Free Fatty Acid Metabolism to Hepatic Injury Markers
Bonet J, Weiss R, Galderisi A, Man C, Caprio S, Santoro N. Adipose Tissue Insulin Resistance in Children and Adolescents: Linking Glucose and Free Fatty Acid Metabolism to Hepatic Injury Markers. AJP Endocrinology And Metabolism 2024 PMID: 39503461, DOI: 10.1152/ajpendo.00270.2024.Peer-Reviewed Original ResearchImpaired glucose toleranceInsulin sensitivity indexAlanine transaminaseInsulin resistanceFree fatty acid metabolismInsulin sensitivityP<10<sup>-6</sup>Years of follow-upMeasurement of liver function testsLiver function testsFree fatty acidsAdipose tissue insulin resistanceAdipose tissue insulin sensitivityHepatic injury markersPlasma alanine transaminaseEstimated insulin sensitivity indexTissue insulin sensitivityMann-Whitney testTissue insulin resistanceType 2 diabetesDevelopment of insulin resistanceProgression of insulin resistanceOral minimal modelCardiometabolic complicationsInsulin-resistant states689 Triple CFTR modulator combination improves glucose tolerance in adolescents with cystic fibrosis: data from the French observational pediatric study MODUL-CF
Weiss L, Galderisi A, Besançon A, Stremler N, Reix P, Wizla N, Rames C, Marguet C, Tatapoulos A, Perrisson C, Dalphin M, Troussier F, Houdouin V, Abely M, Cosson L, Gabsi A, Corvol H, Deneuville E, Sahki D, Bonnel A, Group M, Sermet-Gaudelus I. 689 Triple CFTR modulator combination improves glucose tolerance in adolescents with cystic fibrosis: data from the French observational pediatric study MODUL-CF. Journal Of Cystic Fibrosis 2024, 23: s386-s387. DOI: 10.1016/s1569-1993(24)01527-3.Peer-Reviewed Original ResearchRevisiting the Pattern of Loss of β-Cell Function in Preclinical Type 1 Diabetes.
Martino M, Galderisi A, Evans-Molina C, Dayan C. Revisiting the Pattern of Loss of β-Cell Function in Preclinical Type 1 Diabetes. Diabetes 2024, 73: 1769-1779. PMID: 39106185, DOI: 10.2337/db24-0163.Peer-Reviewed Original ResearchB cell functionBeta cell lossType 1 diabetesLoss of B-cell functionCell lossOral glucose tolerance testPreclinical type 1 diabetesEarly stage diseaseBeta cell destructionTime of diagnosisDestruction of B cellsGlucose tolerance testMonths prior to clinical diagnosisAntibody positivityStage diseaseDisease activityAutoimmune destructionB cellsDisease accelerationInsulin therapyTolerance testInsulin secretionSubmaximal stimuliCell destructionGlucose controlContinuous glucose monitoring in neonates: challenges and opportunities
Puzone S, Diplomatico M, Galderisi A, Montaldo P. Continuous glucose monitoring in neonates: challenges and opportunities. Journal Of Perinatology 2024, 44: 1382-1383. PMID: 38942928, DOI: 10.1038/s41372-024-02041-y.Peer-Reviewed Original ResearchThe Impact of Antenatal Corticosteroids on the Metabolome of Preterm Newborns: An Untargeted Approach
Valerio E, Meneghelli M, Stocchero M, Galderisi A, Visentin S, Bonadies L, Pirillo P, Poloniato G, Giordano G, Baraldi E. The Impact of Antenatal Corticosteroids on the Metabolome of Preterm Newborns: An Untargeted Approach. International Journal Of Molecular Sciences 2024, 25: 5860. PMID: 38892043, PMCID: PMC11172597, DOI: 10.3390/ijms25115860.Peer-Reviewed Original ResearchAntenatal corticosteroidsPreterm infantsPreterm newbornsInvasive ventilationClinical outcomesMass spectrometry-based untargeted metabolomics analysisImpact of antenatal corticosteroidsTiming of antenatal corticosteroidsMetabolomic analysisNeonatal intensive care unitPostnatal clinical outcomesPadova University HospitalRecommended time windowUntargeted metabolomics analysisElevated levelsImprove respiratory outcomesIntensive care unitUrinary metabolomeLabor onsetAnti-inflammatory propertiesMetabolomic profilesDepartment of womenUniversity HospitalCare unitRespiratory outcomesEndpoints for clinical trials in type 1 diabetes drug development
Galderisi A, Marks B, DiMeglio L, de Beaufort C. Endpoints for clinical trials in type 1 diabetes drug development. The Lancet Diabetes & Endocrinology 2024, 12: 297-299. PMID: 38663944, PMCID: PMC11230104, DOI: 10.1016/s2213-8587(24)00097-4.Peer-Reviewed Original ResearchGlucose pattern in children with classical congenital adrenal hyperplasia: evidence from continuous glucose monitoring
Galderisi A, Kariyawasam D, Stoupa A, Quoc A, Pinto G, Viaud M, Brabant S, Beltrand J, Polak M, Samara-Boustani D. Glucose pattern in children with classical congenital adrenal hyperplasia: evidence from continuous glucose monitoring. European Journal Of Endocrinology 2024, 190: l7-l7. PMID: 38668689, DOI: 10.1093/ejendo/lvae042.Peer-Reviewed Original Research